BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.92% | -18.74% | -21.98% | -23.55% | -45.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.08% | -32.92% | -41.66% | -39.65% | -56.32% |
| Operating Income | 1.08% | 32.92% | 41.66% | 39.65% | 56.32% |
| Income Before Tax | 65.38% | 45.93% | 36.21% | 25.73% | -129.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.38% | 45.93% | 36.21% | 25.73% | -129.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.38% | 45.93% | 36.21% | 25.73% | -129.74% |
| EBIT | 1.08% | 32.92% | 41.66% | 39.65% | 56.32% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 75.67% | 60.80% | 53.03% | 45.16% | -86.28% |
| Normalized Basic EPS | 21.68% | -87.92% | -64.61% | -56.86% | 24.92% |
| EPS Diluted | 75.67% | 60.80% | 53.03% | 45.16% | -86.28% |
| Normalized Diluted EPS | 21.68% | -87.92% | -64.61% | -56.86% | 24.92% |
| Average Basic Shares Outstanding | 44.57% | 43.98% | 36.97% | 36.62% | 31.41% |
| Average Diluted Shares Outstanding | 44.57% | 43.98% | 36.97% | 36.62% | 31.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
